GLENMARK TIES UP WITH PAUL CAPITAL OF USA TO DEVELOP DERMATOLOGY PRODUCTS

A A

Glenmark Pharmaceuticals Inc (GPI), a wholly owned US subsidiary of Glenmark Pharmaceuticals, has announced a royalty deal with Paul Capital Partners Royalty fund, an international healthcare investment fund to develop generic prodcuts in the dermatology portfolio for the billion dollar US markets.

Myiris (http://www.myiris.com/newsCentre/storyShow.php?fileR=20060605144308059&secID=fromnewsroom&secTitle=From%20the%20News%20Room&dir=2006/06/05)